Table 2 Demographic Characteristics
Safety population | Â | AC-1202 N = 86 | Placebo N = 66 |
|---|---|---|---|
Age | Mean (± SD) Median | 76.9 (± 8.9) 78.0 | 76.8 (± 7.4) 78.0 |
|  | Range | (52 – 93) | (51 – 89) |
Height (cms) | Mean (± SD) | 165.2 (± 11.4) | 163.2 (± 16.4) |
| Â | Median | 163.8 | 164.6 |
|  | Range | (142.2 – 190.1) | (114.3 – 185.4) |
Weight (kg) | Mean (± SD) | 69.0 (± 15.15) | 70.6 (± 13.7) |
| Â | Median | 69.2 | 67.8 |
|  | Range | (34.3 – 100.2) | (47.6 – 100.2) |
Sex n (%) | Male | 36 (41.7) | 31 (47.0) |
| Â | Female | 50 (58.1) | 35 (53.0) |
Race n (%) | Caucasian | 78 (90.7) | 61 (92.4) |
| Â | Black | 1 (1.2) | 0 |
| Â | Hispanic | 7 (8.1) | 5 (7.6) |
Level of Education n (%) | Graduate/Professional Training | 17 (19.8) | 7 (10.6) |
| Â | Some college | 15 (17.4) | 17 (25.8) |
| Â | High School | 49 (57.0) | 34 (51.5) |
| Â | Grade School | 5 (5.8) | 8 (12.1) |
AD medications n (%)* | Ariceptâ„¢ | 43 (50) | 28 (42.4) |
| Â | Exelonâ„¢ | 11 (12.8) | 11 (16.7) |
| Â | Namendaâ„¢ | 32 (37.2) | 31 (47) |
| Â | Reminylâ„¢/Razadyneâ„¢ | 3 (3.5) | 9 (13.6) |
Genotyped population | Â | AC-1202 N = 67 | Placebo N = 57 |
APOE Genotype n (%) | 3/2 | 4 (6.0) | 2 (3.5) |
| Â | 3/3 | 25 (37.3) | 24 (42.1) |
| Â | 4/2 4/3 | 3 (4.9) 31 (46.3) | 0 21 (36.8) |
| Â | 4/4 | 4 (6.0) | 10 (17.5) |
| Â | Total E4(+) | 38 (56.7) | 31 (54.4) |
| Â | Total E4(-) | 29 (43.3) | 26 (45.6) |
ITT population | Â | AC -1202 N = 77 | Placebo N = 63 |
Baseline MMSE | Mean (± SD) | 19.68 (± 4.48) | 19.48 (± 4.37) |
| Â | Median | 20.00 | 20.00 |
|  | Range | (10 – 28) | (8 – 29) |
| Â | 95% CI | 18.66, 20.69 | 18.37, 20.58 |
Baseline ADAS-Cog | Mean (± SD) | 23.88 (± 9.17) | 23.35 (± 8.7) |
| Â | Median | 23.67 | 23.00 |
|  | Range | (7.00 – 54.33) | (11.33 – 62.00) |
| Â | 95% CI | 21.80, 25.96 | 21.16, 25.54 |